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Persistent infection of human immunodeficiency virus (HIV) takes place in the secondary lymphoid tissues even during
clinically latent stages. The CC chemokines secondary lymphoid tissue chemokine (SLC) and EBI1-ligand chemokine (ELC)
are constitutively expressed in the secondary lymphoid tissues. They share CCR7 expressed on lymphocytes and mature
dendritic cells and play key roles in the trafficking of these types of cells into the secondary lymphoid tissues. Here we report
that growth of both X4 and R5 strains of HIV-1 in activated peripheral blood T cells was enhanced by SLC. The enhancing
effect of SLC was abrogated by pretreatment of cells with pertussis toxin, indicating the involvement of signaling via a
receptor coupled with a Gai class of G-protein. Furthermore, SLC was found to enhance the promoter activity of HIV-1 LTR.
These results suggest that signaling via CCR7 has a strong positive effect on HIV growth. Thus, SLC and ELC may contribute































Chemokines and chemokine receptors constitute im-
ortant regulatory elements in leukocyte emigration and
ymphocyte trafficking (Baggiolini et al., 1994; Rollins,
997; Yoshie et al., 1997). Furthermore, certain chemo-
ine receptors such as CXCR4 and CCR5 function as
ssential entry coreceptors for HIV while chemokines
pecific for these receptors such as SDF-1 and RANTES
re potent inhibitors of HIV infection (Cairns and
’Souza, 1998). Even during asymptomatic stages of HIV
nfection, viral replication persists in the secondary lym-
hoid tissues (Pantaleo et al., 1993; Embretson et al.,
993; Nuovo et al., 1994). Thus, the secondary lymphoid
issues may provide microenvironments that support per-
istent infection and replication of HIV. In lymph nodes
nd other secondary lymphoid tissues, HIV particles are
ostly trapped on the villus processes of follicular den-
ritic cells (FDC) in the germinal centers but these cells
re not the main sites of HIV replication. Numerous
IV-infected CD41 T cells are found in and around ger-
inal centers, in paracortical areas, and around blood
essels. Strong expression of HIV RNA is detected in a
raction of infected CD41 T cells, and the proportion of
hese cells increases upon disease progression (Panta-
eo et al., 1993; Embretson et al., 1993; Nuovo et al.,
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422994). Thus, the mechanisms responsible for persistent
nfection and active replication of HIV in the secondary
ymphoid tissues even in asymptomatic stages of the
isease seem to consist of a combination of processes
uch as mechanical trapping of virions by the FDC net-
ork, homing and sequestration of infected CD41 T cells
n enlarged lymph nodes, and activation of HIV replica-
ion in a fraction of infected CD41 T cells (Pantaleo et al.,
993; Embretson et al., 1993; Nuovo et al., 1994; Tedla et
l., 1996; Wang et al., 1997). In this regard, the proinflam-
atory cytokines IL-6 and TNF-a together with the im-
unoregulatory cytokine IL-2, which are all known to be
eadily produced in the microenvironments of the sec-
ndary lymphoid tissues in response to antigenic and
ther stimuli, have been shown to act highly synergisti-
ally as inducers of viral replication in latently infected,
esting CD41 T cells (Chun et al., 1998).
The secondary lymphoid tissues provide microenvi-
onments where migrating lymphocytes encounter anti-
enic peptides presented by professional antigen-pre-
enting cells and proliferate if properly activated (Gretz et
l., 1996; Butcher and Picker, 1996; Springer, 1994). The
C chemokines SLC (secondary lymphoid-tissue chemo-
ine) (Nagira et al., 1997), also known as 6Ckine (Hedrick
nd Zlotnik, 1997) or exodus-2 (Hromas et al., 1997a), and
LC (EBI1-ligand chemokine) (Yoshida et al., 1997), also
nown as MIP-3b (Rossi et al., 1997) or exodus-1 (Hro-
as et al., 1997b), are constitutively expressed in the T
ell zone of the secondary lymphoid tissues. SLC and

























































































423SECONDARY LYMPHOID TISSUE CHEMOKINES ENHANCE HIV-1 GROWTHells and to attract these types of cells efficiently (Yo-
hida et al., 1998a; Nagira et al., 1998; Willimann et al.,
998; Sozzani et al., 1998; Yanagihara et al., 1998; Gunn et
l., 1998). Both chemokines have been shown to induce
rapid adhesion of rolling T lymphocytes to ICAM-1
nder flow conditions (Campbell et al., 1998a; Gunn et
l., 1998). Furthermore, they are encoded by the genes
losely located on chromosome 9p13 in humans (Nagira
t al., 1997; Yoshida et al., 1997). Thus, these chemokines
re genetically and functionally closely related and are
onsidered to be involved in trafficking and homing of
ymphocytes and dendritic cells (Campbell et al., 1998a;
unn et al., 1998). Because of their constitutive and
elective expression in secondary lymphoid tissues, we
peculated that these chemokines might affect HIV-1
rowth. Here we report that SLC enhances the growth of
4 and R5 strains of HIV-1 in activated T cells. Thus, SLC
s well as ELC may play an important role in persistent
nfection and replication of HIV in the secondary lym-
hoid tissues.
RESULTS AND DISCUSSION
Freshly isolated PBMC were stimulated with PHA for 2
ays and infected with T-cell line-tropic (X4) strain NL432
r macrophage-tropic (R5) strain SF162 at a m.o.i. of 0.1.
fter being washed, infected PBMC were cultured in the
resence of IL-2 to support multiround infection of HIV-1
n activated T cells. Virus production was monitored by
easuring reverse transcriptase (RT) activity in the cul-
ure supernatants. When added together with IL-2, SLC
nhanced the replication of both X4 and R5 strains of
IV-1 (Figs. 1a and 1b). The enhancing effect of SLC on
IV-1 growth was consistently observed with PBMC from
even different donors. The effect of SLC was dose-
ependent with a significant enhancement even at 2 nM
nd a maximal effect at 10 nM for both strains (Fig. 1c).
e further compared the effect of SLC on HIV-1 growth
ith that of other chemokines. PHA-stimulated PBMC
ere infected with a chimeric R5-type clone, NL162env
Tachibana et al., 1997), and cultured for 7 days in the
resence of IL-2 without or with the indicated chemo-
ines at 100 nM (Fig. 1d). While SLC strongly enhanced
iral growth, no other chemokines tested in parallel
howed such an enhancement. As expected, RANTES,
IP-1a, and MIP-1b effectively suppressed the growth of
he R5-type NL162env. In our preliminary experiments,
LC also enhanced the growth of X4 and R5 viruses in
h1 and Th2 cells polarized in vitro from CD41CD45RA1
aive T cells (Imai et al., 1999). Thus, SLC uniquely
nhances HIV-1 growth in activated T cells.
SLC has been shown to act via CCR7, which is ex-
ressed highly selectively in T cells, B cells, and mature
endritic cells (Yoshida et al., 1997, 1998a,b; Nagira et
l., 1998; Campbell et al., 1998b; Willimann et al., 1998;
ozzani et al., 1998; Yanagihara et al., 1998; Gunn et al., g998). Recently, however, murine SLC was also reported
o be capable of signaling via CXCR3 (Soto et al., 1998),
hich is known to be expressed on activated T cells and
unctions as the shared receptor for IP-10, Mig, and I-TAC
Loetscher et al., 1996; Cole et al., 1998). It is thus notable
hat IP-10, a potent and specific ligand for CXCR3, did not
nhance HIV-1 growth at all (Fig. 1d). In our preliminary
xperiments, we also confirmed enhanced HIV-1 growth
y ELC, another specific ligand for CCR7 (Yoshida et al.,
997). Collectively, these results support the notion that
CR7 mediates the enhancing effect of SLC on HIV-1
FIG. 1. Enhanced HIV-1 production by SLC. (a,b) Time course study.
BMC were stimulated with PHA for 2 days and infected with an X4
train of HIV-1 NL432 (a) or an R5 strain of HIV-1 SF162 (b). Infected
BMC were maintained with 20 units/ml of IL-2 without (open circles)
r with SLC at 50 nM (closed circles). RT activity in the culture super-
atants was determined at indicated time points. All assays were done
n triplicate to obtain mean 6 SD. Representative results from three
ndependent experiments are shown. (c) Dose–response study. PBMC
ere stimulated with PHA for 2 days and infected with HIV-1 NL432
squares) or HIV-1 SF162 (circles). Infected PBMC were maintained
ith 20 units/ml of IL-2 without (open symbols) or with indicated
oncentrations of SLC (closed symbols) to determine RT activity in the
ulture supernatants after 7 days. All assays were done in triplicate to
btain mean 6 SD. Representative results from three independent
xperiments are shown. (d) Specificity study. PBMC were stimulated
ith PHA for 2 days and infected with a chimeric R5-strain HIV-1
L162env. Infected PBMC were maintained with 20 units/ml of IL-2
ithout or with indicated chemokines at 400 nM. RT activity in the
ulture supernatants was determined after 7 days. All assays were
one in duplicate. Representative results from two independent exper-
ments are shown. (e) Effect of PTX. PBMC were stimulated with PHA
nd infected with an R5 strain, HIV-1 NL162env. Infected PBMC were
retreated without (open bars) or with (closed bars) 10 ng/ml of PTX for
0 min at 37°C and then supplied with 20 units/ml of IL-2 without or
ith 100 nM SLC. After 7 days, RT activity in the culture supernatants
as determined. All assays were done in triplicate to obtain mean 6





























































































424 NAGIRA ET AL.Since signaling via CCR7 has been shown to be me-
iated by a pertussis toxin (PTX)-sensitive Gai class of
-protein (Nagira et al., 1997), we examined the effect of
TX on SLC-induced enhancement of HIV-1 growth in
HA-stimulated PBMC (Fig. 1e). PTX did not affect the
asal level of HIV-1 production, but effectively sup-
ressed the enhancing effect of SLC on HIV-1 growth.
hus, signaling through Gai is involved in SLC-induced
nhancement of HIV-1 growth.
Since HIV-1 growth requires replication and expres-
ion of the viral genome, we next examined the effect of
LC on viral RNA accumulation and the LTR promoter
ctivity. Northern blot analysis revealed that SLC en-
anced accumulation of viral RNA of both X4 and R5
trains of HIV-1 in T cell blasts (Fig. 2a). For the assay of
he promoter activity, a reporter plasmid consisting of the
irefly luciferase gene driven by HIV-1 LTR was trans-
ected into Hut78 human T cells that had been shown to
xpress CCR7 at high levels (Yoshida et al., 1997). As
FIG. 2. Effects of SLC on HIV-1 RNA accumulation and LTR promoter
ctivity. (a) Northern blot analysis of HIV-1 genomic RNA. PBMC were
timulated with PHA for 2 days, washed, and infected with an X4 strain,
IV-1 NL432, or a chimeric R5 strain, HIV-1 NL162env. Cells were
ultured for 7 days with 20 units/ml of IL-2 without or with indicated
oncentrations of SLC. Total RNA was prepared and separated by
lectrophoresis on 1% agarose gel (0.7 mg/lane). After staining with
thidium bromide (bottom), RNA was transferred onto a nylon mem-
rane and hybridized with a 0.71-kb BssHI–PstI gag fragment of NL432.
he filter was exposed to an X-ray film for 7 days with an intensifying
creen (top). Representative results from two separate experiments are
hown. (b) Enhancement of HIV-1 LTR promoter activity by SLC. A
eporter plasmid containing the firefly luciferase gene under the control
f HIV-1 LTR (pLTR-Luc) (10 mg) and a reporter plasmid containing the
enilla luciferase gene under the control of CMV promoter (pCMV-RL)
0.1 mg) were cotransfected into Hut 78 cells. After 18 h, the cell culture
as subdivided and treated without or with SLC or TARC at indicated
oncentrations. After 24 h, cell lysates were prepared and luciferase
ctivities were determined. All assays were done in triplicate. The ratio
f firefly luciferase activity to renilla luciferase activity is shown as
ean 6 SD of percentage control. Representative results from three
ndependent experiments are shown.hown in Fig. 2b, SLC enhanced the promoter activity in sdose-dependent manner. As a control, we tested the
ffect of another lymphocyte-specific chemokine, TARC
thymus and activation-regulated chemokine), since Hut
8 cells also express its receptor CCR4 at high levels
nd respond vigorously to TARC in chemotaxis assays
Imai et al., 1996, 1997). TARC did not enhance the HIV-1
TR promoter activity at all. Thus, the results support the
otion that the signaling via CCR7 uniquely activates
IV-1 LTR.
Here, we have shown that SLC, the chemokine acting
n CCR7, which is selectively expressed on lymphocytes
nd mature dendritic cells (Nagira et al., 1997; Yoshida et
l., 1997, 1998a,b; Campbell et al., 1998; Willimann et al.,
998; Sozzani et al., 1998; Yanagihara et al., 1998), is
apable of enhancing growth of both X4 and R5 strains of
IV-1 in activated T cells. The enhancing effect is de-
endent on signaling via PTX-sensitive G-protein-linked
athways. No other chemokines examined in parallel
ad such positive effects on HIV-1 growth under our
xperimental conditions. Furthermore, SLC was shown
o enhance the promoter activity of HIV-1 LTR. Thus,
ignaling via CCR7 may uniquely upregulate nuclear
ranscription factors, such as NF-kB, in activated T cells
o augment HIV transcription. The exact molecular mech-
nisms, however, remain to be elucidated.
While RANTES, MIP-1a, and MIP-1b, the b-chemo-
ines specific for CCR5, are potent inhibitors of HIV-1
ntry via CCR5 (Cairns and D’Souza, 1998), the same
hemokines were also shown to stimulate the replication
f primary HIV-1 strains in macrophages (Schmidtmay-
rrova et al., 1996). Similarly, RANTES, MIP-1a, and
IP-1b were shown to enhance replication of a R5 strain
f HIV-1 BaL in monocytes and macrophages via PTX-
ensitive G-protein-linked pathways when the cells had
een exposed to these b-chemokines prior to HIV infec-
ion (Kelly et al., 1998). Thus, the roles of these b-che-
okines on infection of R5-type HIV-1 can be dichoto-
ous depending on the type of host cell and timing of
reatment. Furthermore, SDF-1, the ligand for CXCR4/
usin and a potent entry inhibitor of X4 strains of HIV
Bleul et al., 1996; Oberlin et al., 1996), was shown to
nhance the growth of R5-type HIV-1 in P4C5 indicator
ells (HeLa CD41CXCR41CCR51LTR-lacZ1) by promot-
ng the transactivation of LTR by Tat (Marechal et al.,
999). SDF-1 was also shown to be possibly responsible
or enhanced apoptosis of CD81 T cells in HIV-infected
atients (Herbein et al., 1998). Thus, the effects of SDF-1
n HIV-1 infection and AIDS pathogenesis can also be
ultiple and opposite. Our present results are reminis-
ent of these previous findings and extend them by
howing that SLC, the ligand for CCR7, enhances repli-
ation of both R5 and X4 types of HIV-1 at least in part
hrough enhancing the LTR promoter activity. So far there
re no HIV or SIV strains that have been shown to use
CR7 as an entry coreceptor, even though CCR7 is








































































425SECONDARY LYMPHOID TISSUE CHEMOKINES ENHANCE HIV-1 GROWTHells, the important target cells of HIV and SIV. Further-
ore, SLC and ELC, the specific ligands for CCR7, are
onstitutively expressed in the secondary lymphoid tis-
ues where persistent infection of HIV and SIV takes
lace. Thus, SLC and ELC may constitute important pos-
tive factors for persistent infection of HIV-1 in the sec-
ndary lymphoid tissues.
MATERIALS AND METHODS
Cells. Various human cell lines was cultured in RPMI
640 supplemented with 10% FCS. PBMC were isolated
rom EDTA-treated venous blood samples obtained from
ealthy adult donors by using Ficoll-Paque (Pharmacia
iotech). PBMC were suspended in RPMI 1640 supple-
ented with 10% FCS and stimulated with PHA-M at
/100 (Gibco BRL) for 2 days. Stimulated PBMC were
ashed and maintained in culture with IL-2 (Shionogi,
saka, Japan). Cells were treated with chemokines at
arious time points.
Chemokines and HIV-1 strains. Production and purifi-
ation of SLC, ELC, TARC, liver and activation-regulated
hemokine, pulmonary and activation-regulated chemo-
ine, SCM-1 (single C motif-1)/lymphotactin, and eotaxin
ere described previously (for references, see Yoshie et
l., 1997). MIP-1a, MIP-1b, MCP-1, MCP-2, MCP-3, RAN-
ES, eotaxin-2, IL-8, IP-10, and SDF-1a were purchased
rom Peprotech (Rocky Hill, NJ). An X4 strain of HIV-1
L432, a R5 strain of HIV-1 SF162, and a chimeric R5
train of HIV-1 NL162env in which the env region (EcoRI–
amHI) of the infectious clone pNL432 was replaced
ith that of SF162 were all described previously (Tachi-
ana et al., 1997).
HIV-1 infection. PHA-stimulated PBMC were infected
ith HIV-1 at a m.o.i. of 0.1 at 37°C for 60 min and
ashed once. Infected PBMC were suspended at 1 3
05/ml and cultured in RPMI 1640 containing 10% FCS
nd 20 units/ml of IL-2 without or with an indicated
hemokine. RT activity in the culture supernatants was
etermined as described previously (Sato et al., 1995).
Northern blotting analysis. Total RNA extracted from
IV-1-infected PBMC was separated by electrophoresis
n 1% agarose gel containing 0.66 M formaldehyde,
lotted onto a filter, and hybridized with the BssHI–PstI
.71-kb gag region fragment derived from pNL432 in the
uick-hybridization solution (Amersham) at 65°C for 60
in. After stringent washes in 0.13 SSC and 0.1% SDS at
5°C, filters were exposed to X-ray films with intensifying
creens for 7 days.
Luciferase reporter assay. This was carried out essen-
ially as described previously (Hori et al., 1998). In brief,
reporter plasmid containing the firefly luciferase gene
riven by HIV-1 NL432 LTR (pLTR-Luc) and a reporter
lasmid containing the renilla luciferase reporter gene
riven by the CMV promoter (pCMV-RL) were cotrans-ected into human Hut78 T cells. After 18 h, the cellulture was subdivided into several groups and treated
s indicated for 24 h. After that, cell lysates were pre-
ared and the luciferase assay was done in triplicate.
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